CoviD-XIX, FRU a vel flu B participem eadem symptoms, faciens durum ad distinguere inter tres virus infections.differial diagnosis ad identify target curatio exigit combined probatio ad identify target treatment exigit combined testando ad identify target exigit exigit ad identify virum (es) infici.
Necessitates
Accurate differentiale diagnosis est crucial ad dirigi oportet antiviral illic.
Licet sharing eandem symptoms, Covi, XIX, morbum et flu B infectiones opus diversis antiviral curatio. Influenza potest tractata neuraminidase inhibitors et gravibus Covi-XIX cum Remdesivir / Sotrovimab.
Positive effectus in unum virum non sit quod vos es a aliis. Co-Infectiones augmentum metus de gravibus morbo, hospitalization, mors debitum ad synergistic effectus.
Accurate diagnosis per multiplex temptationis est crucial ad dirigi oportet antiviral illic, praesertim cum potential co-infectiones per apicem respiratoriorum virus tempore.
Nostra Solutions
Macro & Micro-test estSars, Cov-II, Influenza A & B antigen combined deprehensio, Differiatibus morbum a, flu B et Covi XIX una cum potential multi-infectiones per respiratoriorum morbo tempore;
Celeriter Testing of plures respiratorii infectiones, inter Sars, Cov-II, morbum A, et flu B per unum specimen;
Plene integrated Test habena cum una tantum application area et una specimen opus ad differentiam in Covi XIX, et morbum et morbum b;
IV gradibus solum ad celeri Results in tantum 15-20 min, enabling citius orci consilium faciens.
Multiple Sample Genera: nasopharyngeal, oropharyngeal et nasi;
Storage temperatus: IV -30 ° C;
PLUTEUM Vita: XXIV menses.
Multiple missiones in hospitalium, clinics, civitas centers, pharmacies, etc.
| SARS-CoV-2 | Flu A | FluB | |
| Sensibilitas | 94.36% | 94.92% | 93,79% |
| Specifica | 99,81% | 99.81% | 100.00% |
| Accuratio | 98,31% | 98.59% | 98.73% |
Post tempus: Jan-18-2024